Health Economics›Hairy cell leukemia›Relapsed or refractory

Relapsed or refractory

Hairy cell leukemia · 7 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Cladribine and Rituximab Variant #01	—	R 48 077	21d	—	—	~6	~R 288 462 indirect	—
Bendamustine and Rituximab (BR) Variant #01	—	R 33 874	28d	~39.6 mo	—	~7	~R 237 120 PFS proxy · indirect	18
Vemurafenib monotherapy Variant #01	—	R 13 464	28d	~7.2 mo	~15.5 mo	~2	~R 26 928 PFS proxy · indirect	4
Rituximab monotherapy Variant #09 Partial	—	—	28d	~20.3 mo	—	~1	—	17
Moxetumomab pasudotox monotherapy Variant #01 Partial	—	—	28d	—	—	~6	—	—
Interferon alfa-2a monotherapy Variant #01 Partial	—	—	7d	~5.4 mo	~17.5 mo	~2	—	10
Interferon alfa-2b monotherapy Variant #01 Partial	—	—	28d	~13.2 mo	—	~23	—	2

7 of 7 regimens shown